The decomposition rate and bleaching efficacy of in-office bleaching gels with different pHs: a randomized controlled trial

Fernanda Novak Gumy,Karine Letícia da Silva,Marcela Novak Gumy,Heloisa Forville,Deisy Cristina Ferreira Cordeiro,Michael Willian Favoreto,Alessandro D Loguercio,Alessandra Reis

DOI: https://doi.org/10.1007/s00784-024-05821-0

2024-07-23

Abstract:Background: To evaluate the decomposition rate of active hydrogen peroxide (HP) and bleaching efficacy during in-office bleaching using high-concentration HP gels with different pHs. Method: A randomized, parallel, double-blind controlled trial was conducted with 40 volunteers randomized into four groups (pH 5.4; pH 7.0; pH 7.7, and pH 8.0). During the first session in-office bleaching, approximately 0.01 g of the gel was collected and titrated with potassium permanganate to obtain the concentration of active HP and pH values were measured using an electrode. Bleaching efficacy was assessed using a spectrophotometer [∆Eab, ∆E00, and WID], Vita Classical and Vita Bleachedguide scales [∆SGU]. The decomposition rate of HP concentration and pH values change were calculated using ANOVA one-way. The bleaching efficacy was assessed using two-way repeated measures ANOVA. Tukey's test was applied as a post-hoc test (p < 0.05). Results: All gels experienced decreasing HP concentration over time. pH 5.4 gel showed greatest reduction after 50 min (p < 0.001). pH 8.0 and 7.7 gels remained stable; pH 5.4 remained acidic, while pH 7.0 turned acidic (p < 0.001). No significant difference in bleaching degree was observed among gels. They all showed a similar and clinically important color change after two clinical sessions, remained stable 1-month post-treatment (p > 0.05). Conclusions: All bleaching gels kept at least 70% of their HP content after 50 min, suggesting that there is a surplus of HP. They provided similar whitening efficacy 1-month after bleaching. Practical implications: It is possible that lower HP concentrations may be equally effective in achieving desired results while reducing the potential for side effects. Clinical trial registry name: RBR-35q7s3v.